{
    "body": "Is hydroxyurea usually used to treated infectious disease?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21196716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26275071", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27677923", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15307105", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20008183"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0020402", 
            "o": "hydroxyurea"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0020402", 
            "o": "http://linkedlifedata.com/resource/umls/label/A0481276"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0481276", 
            "o": "hydroxyurea"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0020402", 
            "o": "http://linkedlifedata.com/resource/umls/label/A7996376"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7996376", 
            "o": "hydroxyurea"
        }
    ], 
    "ideal_answer": [
        "Hydroxyurea represents the only available disease-modifying therapy for Sickle Cell Anemia (SCA)."
    ], 
    "exact_answer": "no", 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:10923", 
        "http://www.biosemantics.org/jochem#4275774", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275774", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006450", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006918"
    ], 
    "type": "yesno", 
    "id": "58dbbdac8acda3452900001e", 
    "snippets": [
        {
            "offsetInBeginSection": 156, 
            "offsetInEndSection": 294, 
            "text": "Hydroxyurea represents the only available disease-modifying therapy for SCA, and has proven safety and efficacy in high-resource countries", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275071", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1579, 
            "offsetInEndSection": 1777, 
            "text": "In conclusion, the data here presented suggests that hydroxyurea may prevent priapism attacks in sickle cell disease, probably at higher doses than usually prescribed for painful crisis prevention..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 75, 
            "text": "Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196716", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 405, 
            "offsetInEndSection": 546, 
            "text": "t may also attenuate optimal response to hydroxyurea therapy, the only effective and practical treatment option for SCD in sub-Saharan Africa", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 82, 
            "text": "Hydroxyurea is one of the most successfully used therapies for sickle cell disease", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 252, 
            "text": "Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008183", 
            "endSection": "abstract"
        }
    ]
}